Therefore, the development of drugs targeting the miR-370-3p-PDLIM1-Wnt/β-catenin signaling axis, combined with other strategies, may be helpful to improve the clinical treatment of CML. This evidence concerns the gene PDLIM1 and chronic myelogenous leukemia, BCR-ABL1 positive.